Full-Time

Laboratory Services Manager

Stability

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

No salary listed

Bristol, PA, USA

In Person

Bachelor's

Category
Biology & Biotech
Required Skills
GMP

Get referred to Abzena

See people who can refer or advise you

Requirements
  • A bachelor's degree in Life Sciences, Chemistry, Biochemistry, Biology, or a related field is required.
  • Eight to ten years of progressive laboratory operations experience, including a minimum of three years in a supervisory or management role with direct reports, is required.
  • Demonstrated experience managing laboratory operations in a GMP-regulated pharmaceutical or biotechnology environment is required.
  • Hands-on experience with sample management and logistics, as well as laboratory facilities, safety, and instrument management, is required.
  • Experience leading teams through regulatory inspections, including FDA, EMA, or equivalent inspections, is required.
  • Experience building or significantly improving laboratory management systems, including SOPs, training programs, preventive maintenance programs, and inventory systems, is required.
  • Strong vendor and contract management experience is required.
Responsibilities
  • Directly manage, mentor, and develop all Laboratory Services technicians; set expectations, provide feedback, and conduct formal performance reviews.
  • Build individual development plans for each technician aligned with role focus and career trajectory.
  • Assign and prioritize workload across the team and proactively redistribute work to prevent missed or delayed operational tasks.
  • Serve as the escalation point for sample integrity concerns, safety incidents, equipment failures, and vendor disputes.
  • Recruit, onboard, and train new technicians; ensure onboarding programs are structured, documented, and executed consistently.
  • Own and continuously improve sample management SOPs covering receipt, storage, chain of custody, retention, and disposal.
  • Establish storage condition standards and monitoring protocols for samples, review deviations, and approve corrective actions.
  • Set the framework for third-party laboratory management, including vendor lists, service agreements, turnaround expectations, and result filing.
  • Oversee sample shipments, temperature-controlled logistics, and regulatory import/export documentation.
  • Define and govern the certificate of analysis and reference/stability standard management system.
  • Review and approve the stability trendsheet process and ensure timely review and escalation.
  • Review the sample tracking database and drive corrective action for identified gaps.
  • Act as the primary contact with clients, quality assurance, and project teams regarding sample status, integrity issues, and deviations.
  • Own the laboratory inspection-readiness strategy and hold the team accountable to audit-ready standards.
  • Lead the laboratory through external audits and regulatory inspections and respond to inspector observations.
  • Own the laboratory safety program, including safety reports, corrective actions, incident investigations, and EHS compliance.
  • Define and govern instrument upkeep and preventive maintenance programs and maintain instrument qualification status.
  • Set procurement strategy for laboratory capabilities and equipment, including business cases, vendor selection, and procurement lifecycle oversight.
  • Govern the laboratory training program and ensure current training, structured training triggers, and sign-off.
  • Oversee laboratory housekeeping and upkeep and escalate facility issues to facilities or EHS partners.
  • Manage vendor and service-contract relationships for laboratory instruments and infrastructure.
  • Serve as the operational liaison between Laboratory Services and Analytical Services scientific teams.
  • Attend project and department meetings to assess testing demands, timelines, and operational impacts.
  • Partner with quality assurance and quality control on quality-system requirements, audits, inspections, deviation investigations, and CAPA implementation.
  • Collaborate with process development, manufacturing, and supply chain teams on sample expectations, material requirements, and shipment coordination.
  • Negotiate vendor service agreements, enforce contract terms, and escalate poor performance.
  • Represent Laboratory Services in cross-functional continuous-improvement initiatives and drive solutions to operational pain points.
  • Ensure sample management, safety, instrument maintenance, and inventory activities comply with GMP requirements and internal quality standards.
  • Own Laboratory Services SOPs, maintain the SOP register, and ensure timely review and revision.
  • Review and approve deviations, non-conformances, and change controls related to laboratory operations.
  • Maintain laboratory management records in an organized, compliant, and inspection-ready state.
  • Support quality assurance laboratory investigations by providing records and technical context.
  • Drive data integrity according to ALCOA+ principles.
  • Evaluate operational efficiency, reliability, and compliance and implement improvements.
  • Lead implementation of systems and technologies such as LIMS upgrades, inventory automation, and digital maintenance tracking.
  • Track operational metrics and use data to drive decisions.
  • Benchmark laboratory practices against industry standards and regulatory expectations.
  • Document and standardize best practices across both technician role areas.
Desired Qualifications
  • An advanced degree is a plus.
  • EHS training or a formal safety coordinator background is an asset.

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Get referred to Abzena

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2025 CEO Geoffrey Glass unified strategy after chairman tenure.
  • September 2025 GS knockout launches expand standalone and GMP cell-line revenue.
  • 2026 Tasrif and Promatix projects show customer demand for Abzena platforms.

What critics are saying

  • Lonza, WuXi, and Samsung Biologics outscale Abzena on global capacity.
  • Abzena's 2025 class-action settlement keeps employment claims visible to candidates.
  • If ADC and AOC programs slow, expanded CDMO capacity sits underutilized.

What makes Abzena unique

  • Abzena owns integrated discovery-to-GMP workflows for complex biologics and bioconjugates.
  • ThioBridge and AbZelectPRO KO platforms speed ADC and afucosylated protein programs.
  • Frost & Sullivan named Abzena a 2026 leader for ADC CDMOs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Abzena
Jul 15th, 2026
Outsourced Pharma capability Update - Cell Line Development June 2026.

Outsourced Pharma capability Update - Cell Line Development June 2026. Early cell line decisions define everything that comes after: yield, stability, manufacturability, and timelines. That's why Abzena PLC presented at the Outsourced Pharma Capabilities Update on June 16th, which is focused on Cell Line Development strategies. Abzena's VP & Scientific Leader of Cell Line Development, John E. Gill IV, presented a talk on "Integrated Cell Line Development: Manufacturability to GMP-Ready by Design." John broke down how a truly integrated approach, one built with GMP readiness and manufacturability in mind from day one, changes the trajectory of complex biologic programs. The result: - Accelerated timelines to GMP - Reduced downstream risk - Cell lines engineered to meet GMP standards, not retrofitted to them - A smoother, faster path from discovery to clinical & commercial manufacturing When GMP readiness is designed in from the start, not added later, programs don't stall. They move forward faster.

Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth